An independent two-stage DCF analysis by a frontier AI model.
IQVIA possesses a near-monopolistic advantage in healthcare data through its repository of 1.2 billion non-identified patient records. This massive dataset is the foundation of an incredibly durable economic moat. The integration of its advanced analytics directly into the complex R&D and commercial workflows of major pharmaceutical companies ensures immense switching costs and strong pricing power.
Beyond its data assets, IQVIA operates as a vital clinical research organization (CRO), effectively capturing value at both ends of the drug development lifecycle. The combination of high-margin analytics and mission-critical clinical services generates highly predictable, compounding free cash flow, presenting significant long-term intrinsic value.
A 9.0% growth rate anticipates strong and compounding free cash flow generation. The high-margin Technology & Analytics segment combined with the sticky, recurring nature of multi-year clinical trial contracts supports robust, near double-digit cash flow expansion.
An 8.0% discount rate reflects the highly recurring revenue model and the indispensable nature of its data assets within the life sciences sector. This relatively low risk premium is justified by its strong competitive moat.
A 3.0% terminal rate represents a conservative long-term growth outlook, slightly outpacing general inflation due to the structural, secular growth of global healthcare expenditures and medical research.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $509.70 | $407.76 | $339.80 | $291.26 | $254.85 |
| 2.5% | $582.51 | $453.07 | $370.69 | $313.66 | $271.84 |
| 3.0% | $679.60 | $509.70 | $407.76 | $339.80 | $291.26 |
| 3.5% | $815.52 | $582.51 | $453.07 | $370.69 | $313.66 |
| 4.0% | $1,019.40 | $679.60 | $509.70 | $407.76 | $339.80 |
■ Undervalued vs current price ■ Overvalued vs current price
This growth rate reflects the expanding margins of its Technology & Analytics division and the increasing volume of complex, data-driven clinical trials. As AI integration deepens its product offerings, cash flow generation is expected to accelerate steadily.
While global data privacy regulations pose a constant operational headwind, IQVIA's sophisticated anonymization processes and massive scale actually turn compliance into a competitive advantage, creating a significant barrier to entry for smaller competitors.
No. This DCF model relies on specific forward-looking assumptions regarding clinical trial volumes and R&D spending. It cannot account for sudden regulatory shifts in global healthcare policies or black swan macroeconomic events.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.